PT - JOURNAL ARTICLE AU - Ray K Iles AU - Jason K IIes AU - Raminta Zmuidinaite AU - Anna Gardiner AU - Jonathan Lacey AU - Stephen Harding AU - Jonathan Heeney AU - Helen Baxendale TI - Direct detection of humoral marker corelates of COVID-19, glycated HSA and hyperglycosylated IgG3, by MALDI-ToF mass spectrometry AID - 10.1101/2021.07.08.21260186 DP - 2021 Jan 01 TA - medRxiv PG - 2021.07.08.21260186 4099 - http://medrxiv.org/content/early/2021/07/10/2021.07.08.21260186.short 4100 - http://medrxiv.org/content/early/2021/07/10/2021.07.08.21260186.full AB - The prefusion Spike protein of SARS-CoV2 binds advanced glycation end product (AGE) glycated human serum albumin (HSA) and a higher mass, hyperglycosylated/glycated, IgG3, as determined by matrix assisted laser desorption mass spectrometry (MALDI-ToF MS). We set out to investigate if the total blood plasma of patients who had recovered from acute respiratory distress as a result of COVID-19, contained more glycated HSA and higher mass (glycosylated/glycated) IgG3 than those with only clinically mild or asymptomatic infections. A direct dilution and disulphide bond reduction method was development and applied to plasma samples from SARS-CoV2 seronegative (N = 30) and seropositive (N = 31) healthcare workers and 38 convalescent plasma samples from patients who had been admitted with acute respiratory distress syndrome (ARDS) associated with COVID-19.Patients recovering from COVID-19 ARDS had significantly higher mass, AGE-glycated HSA and higher mass IgG3 levels. This would indicate that increased levels and/or ratios of hyper-glycosylation (probably terminal sialic acid) IgG3 and AGE glycated HSA may be predisposition markers for development of ARDS as a result of COVID-19 infection. Furthermore, rapid direct analysis of plasma samples by MALDI-ToF MS for such humoral immune correlates of COVID-19 presents a feasible screening technology for the most at risk; regardless of age or known health conditions.Competing Interest StatementThe authors have declared no competing interest.Clinical Trialnot applicableFunding StatementThis study was undertaken by the Humoral Immune Correlates to COVID-19 (HICC) consortium, funded by the UKRI and NIHR; grant number G107217 (COV0170 - HICC: Humoral Immune Correlates for COVID-19). RKI is also funded by NISAD Ideell Forening (charitable association) Organisationsnummer 802528-6157Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:approved by Research Ethics Committee Wales, IRAS: 96194 12/WA/0148. Amendment 5All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesUpon request to corresponding authorHCWHealth care workersARDSAcute respiratory distress syndromeITUIntensive Therapy unitAGEadvanced glycation end productsMALDI-ToFMatrix assisted laser desorption ionization – time of flightHSAHuman serum albuminIgG3Immunoglobin G subtype 3